EZH2 and diffuse large B-cell lymphoma: EZH2 inhibitors can significantly restore HLA expression in EZH2-mutated human DLBCL cell lines, suggesting that complementary therapeutic approaches combining ICIs with epigenetic reprogramming may reverse the resistance to ICIs (Ennishi et al., 2019).